Trade Celularity Inc. - CELU CFD

Celularity Inc. Company profile

About Celularity Inc

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic T cells engineered with a chimeric antigen receptor (CAR) (CAR-T) cells, natural killer (NK) cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, infectious and degenerative diseases. It has four placental-derived allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which resulted in four key cell therapeutic programs: CyCART-19, CYNK-001, CYNK-101 and APPL-001, focused on six initial indications. Its CyCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is developing for the treatment of acute myeloid leukemia (AML), a blood cancer, and for glioblastoma multiforme (GBM), a solid tumor cancer, and COVID-19.

Financial summary

BRIEF: For the six months ended 30 June 2021, Celularity Inc revenues was not reported. Net income totaled $30.9M vs. loss of $5.7M. Net income reflects Change in fair value of warrant liabilit increase from $6.6M (expense) to $34.5M (income), Unrealized gain on marketable securities decrease from $42K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to $0.70.

170 Park Ave
FLORHAM PARK
NEW JERSEY 07932
US